Autoimmune hepatitis, from mechanisms to therapy.

Area of Science:

• Hepatology
• Immunology
• Genetics

Background:

• Autoimmune hepatitis (AIH) was first described in 1950 and initially termed "lupoid hepatitis" due to antinuclear antibodies.
• The disease concept was solidified in 1965 as "autoimmune hepatitis," acknowledging the role of autoimmunity.
• Early studies in the 1960s and 1970s established the efficacy of immunosuppressive therapies like glucocorticoids and azathioprine.

Purpose of the Study:

• To provide a historical overview of autoimmune hepatitis (AIH) research.
• To highlight the evolution of understanding AIH's serological and genetic heterogeneity.
• To discuss current research directions and the need for standardized diagnostic approaches.

Main Methods:

• Historical review of scientific literature and key research milestones.
• Identification and characterization of autoantibodies and associated genes.
• Analysis of clinical manifestations, disease behavior, and treatment outcomes across diverse populations.

Main Results:

• The association between AIH and HLA alleles, first noted in 1972, remains significant.
• Numerous autoantibodies targeting endoplasmic reticulum and liver antigens have been identified.
• AIH exhibits significant immunoserological and genetic heterogeneity, influencing clinical presentation and treatment response.

Conclusions:

• AIH is a heterogeneous disease with varying clinical courses and treatment outcomes influenced by genetics and geography.
• Ongoing research focuses on refining diagnostic criteria, prognostic indices, and treatment algorithms.
• Standardized serological testing is crucial for reliable AIH diagnosis and management.